Clinical pharmacokinetics and delivery of bovine superoxide dismutase

Clin Pharmacokinet. 1995 Jan;28(1):17-25. doi: 10.2165/00003088-199528010-00003.


Experimentally, superoxide dismutase (SOD) protects against cytotoxological and histotoxological effects of superoxide anions, which play a fundamental role where inflammatory processes are involved. Currently, only bovine copper containing SOD (Cu-SOD) is available for clinical application in the treatment of patients with various arthritic diseases. The intramuscular route is the principal route to administer usual dosages of bovine Cu-SOD 4 to 32mg, 2 or 3 times weekly. A single dose corresponds to an optimal dose ranging from 30 to 200 micrograms/kg, determined from an established dose-response curve. After intramuscular injection of bovine Cu-SOD 8, 16 and 32mg the peak plasma concentration occurs 4 to 8 hours postdose and is 0.05, 0.16 and 0.39 mg/L, respectively. Clinically this metallo-protein is particularly effective for the treatment of inflammation and toxicity resulting from ionising irradiations, ischaemia and tumours. The major advantages of liposomally encapsulated bovine Cu-SOD are its improved pharmacokinetic characteristics, leading to a longer plasma half-life and a slower release of free bovine Cu-SOD. In humans, bovine Cu-SOD (free or liposomal), although a foreign protein, is well tolerated and produces no acute or delayed toxic effects.

Publication types

  • Review

MeSH terms

  • Animals
  • Arthritis / drug therapy
  • Bronchopulmonary Dysplasia / drug therapy
  • Clinical Trials as Topic
  • Free Radicals / metabolism
  • Humans
  • Infant, Newborn
  • Liposomes
  • Male
  • Penile Induration / drug therapy
  • Proctitis / drug therapy
  • Radiotherapy
  • Superoxide Dismutase / administration & dosage*
  • Superoxide Dismutase / pharmacokinetics*
  • Superoxide Dismutase / pharmacology


  • Free Radicals
  • Liposomes
  • Superoxide Dismutase